HABIB DABLE

Habib Dable is a distinguished Venture Partner at RA Capital, a leading investment firm dedicated to the life sciences and biotechnology sectors. In this pivotal role, Mr. Dable leverages his profound operational and strategic expertise to identify, evaluate, and support innovative companies poised to transform healthcare. His contributions are instrumental in guiding RA Capital's portfolio firms through critical stages of development, commercialization, and strategic growth.

Mr. Dable's career trajectory is marked by significant leadership positions in the pharmaceutical and biotechnology industries. Most notably, he served as the President and Chief Executive Officer of Acceleron Pharma, a biopharmaceutical company focused on developing therapies for serious and rare diseases. Under his leadership, Acceleron achieved remarkable success, culminating in its acquisition by Merck for an impressive $11.5 billion. This tenure showcased his exceptional ability to drive drug development from early stages through to market success, particularly in areas like rare blood disorders and oncology.

Prior to his impactful role at Acceleron, Habib Dable held several senior executive positions at Bayer AG. He served as President of Bayer's Pharmaceuticals division in the United States, overseeing a vast portfolio and significant market presence. His global experience at Bayer also included leading the Specialty Medicine business unit, where he was responsible for strategic direction and commercial execution across multiple therapeutic areas. Furthermore, Mr. Dable's extensive background includes various leadership roles at Baxter International, further solidifying his comprehensive understanding of the global healthcare landscape.

At RA Capital, Habib Dable's deep insights into drug discovery, clinical development, regulatory pathways, and commercial strategy are invaluable. He works closely with management teams, offering guidance on everything from pipeline prioritization to market access, ensuring that promising scientific advancements translate into tangible patient benefits. His focus areas align with RA Capital's mission to invest in companies developing novel therapeutics for unmet medical needs, including oncology, hematology, rare diseases, and other high-impact therapeutic areas. His proven track record of building and scaling successful biotech companies makes him a critical asset in RA Capital's pursuit of groundbreaking life science investments.